GenMark Diagnostics Acquires License to HCV Genotyping Patent Estate
Published: Nov 02, 2010
CARLSBAD, Calif.--(BUSINESS WIRE)--GenMark Diagnostics, Inc. (NASDAQ:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States. The agreement includes an option to extend the license on a global basis. The financial terms of the license transaction were not disclosed.